Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cytos Biotech Slashes Staff, Research
by Lisa M. Jarvis
August 22, 2011
| A version of this story appeared in
Volume 89, Issue 34
Cytos Biotechnology will reduce its workforce from 82 to about 10, and it is abandoning work on early-stage projects to focus its resources on CYT003-QbG10, a combination of a virus-like particle and synthetic DNA fragment that is in Phase II trials for allergies and asthma. Wolfgang Renner has resigned as CEO, and Thomas Hecht, current chairman of Cytos’ board, will take over executive chairman duties. Cytos is struggling to find a way to pay off a convertible bond of $52 million, due on Feb. 20, 2012. The Zurich-based company says it could still be short by $22 million come February.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter